A5030480320- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Calcium signaling and nucleotide metabolism
- Vascular Tumors and Angiosarcomas
- Cancer-related Molecular Pathways
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Blood disorders and treatments
- Monoclonal and Polyclonal Antibodies Research
- Soft tissue tumor case studies
- Bone Tumor Diagnosis and Treatments
- Single-cell and spatial transcriptomics
- Multiple Myeloma Research and Treatments
- Kruppel-like factors research
- Viral-associated cancers and disorders
- Breast Implant and Reconstruction
- Advanced Breast Cancer Therapies
- Multiple and Secondary Primary Cancers
- Tumors and Oncological Cases
National Center for Epidemiology
2021-2023
Unified Szent István and Szent László Hospital
2009-2022
Országos Pszichiátriai és Neurológiai Intézet
1997-2022
Semmelweis University
2021
Országos Idegsebészeti Tudományos Intézet
2007-2019
Országos Reumatológiai és Fizioterápiás Intézet
2018-2019
Országos Gyógyintézeti Központ
2007-2014
University of Szeged
2012
Royal Liverpool University Hospital
2002-2005
University of Liverpool
2001-2005
Abstract The Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for patients with chronic lymphocytic leukemia (CLL), despite extensive heterogeneity in this disease. To define the underlining regulatory dynamics, we analyze high-resolution time courses of CLL, combining immune-phenotyping, single-cell transcriptome profiling, and chromatin mapping. We identify a consistent program starting sharp decrease NF-κB binding CLL cells, which is followed by reduced...
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on immunoglobulin heavy variable (IGHV) somatic hypermutation (SHM) status. In this study, we assessed nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) pre-treatment samples from 4580 CLL, using time-to-first-treatment (TTFT) as primary end-point relation to IGHV SHM Mutations were detected 1588 (34.7%)...
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or TP53 defect, BTK and phospholipase C gamma 2 ( PLCG2 ) mutations representing the predominant mechanisms conferring secondary resistance. To understand landscape of genomic changes dynamics subclonal architecture associated treatment, an ultra‐deep next‐generation sequencing analysis 30 recurrently mutated genes was performed...
Abstract Chronic lymphocytic leukemia (CLL) is a highly heterogeneous disease in which interaction of the malignant cells with antigen thought to play key role. Individual CLL-cell clones markedly differ their ability respond B-cell receptor ligation, but mechanism underlying frequent hyporesponsiveness incompletely understood. Our aim was further clarify extent and cause signaling abnormality CLL assign pathophysiologic relevance presence or absence responsiveness. We show that...
Summary The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has revolutionised the therapeutic landscape of chronic lymphocytic leukaemia (CLL). Acquired mutations emerging at position C481 in BTK domain are predominant genetic alterations associated with secondary resistance. To assess correlation between disease progression, and emergence temporal dynamics most common resistance mutation C481S , sensitive (10 −4 ) time‐resolved screening was performed 83 relapsed/refractory CLL patients...
Background Prognostic risk stratification according to acquired or inherited genetic alterations has received increasing attention in acute myeloid leukemia recent years. A germline Janus kinase 2 haplotype designated as the 46/1 been reported be associated with an predisposition myeloproliferative neoplasms, and also normal karyotype. The aim of this study was assess prognostic impact on disease characteristics treatment outcome leukemia.Design Methods rs12343867 single nucleotide...
Background: Serum β2-microglobulin (β2m) has been established as a marker of disease activity in malignancies, autoimmune conditions and infections. Despite its important role prognosis assessment monitoring, relatively few studies are available on expression healthy individuals. Furthermore, interpretation results is hampered by the variety reference limits due to differences methodology, sample population statistics.
Both CD38 expression and increased cell size are features of B-lymphocyte activation have been implicated as adverse prognostic factors in B-cell chronic lymphocytic leukaemia (CLL). We therefore examined the relationship between these two variables by FACS analysis 140 consecutive CLL patients. Using mean forward-angle light scatter (FSC) a measure size, circulating B lymphocytes were found to be significantly larger "CD38-positive" cases (those which antigen was expressed at least 20%...
The Val617Phe point mutation of Janus kinase 2 gene is believed to participate in the pathogenesis myeloproliferative syndrome characterised by clonal alteration hematopoetic stem cells. According current results, frequency activating around 80% polycythaemia vera, 35% essential thrombocythaemia, and 50% chronic idiopathic myelofibrosis. diagnoses thrombocythaemia myelofibrosis were so far based on exclusion secondary factors as well bone marrow biopsy histology. goal present work was...
Introduction: Fertility preservation or oncofertility is a relatively new interdisciplinary field dealing with the of female and male reproductive functions before administration gonadotoxic therapy. Despite recommendations from different international scientific bodies, Hungary still does not have national fertility network, patient referral unorganised. Objective: As first step towards establishing program, study was designed to evaluate Hungarian oncologists' knowledge, attitudes practice...
Abstract Chronic lymphocytic leukemia (CLL) is a genetically, epigenetically, and clinically heterogeneous disease. Despite this heterogeneity, the Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for vast majority of CLL patients. To define underlining regulatory program, we analyzed high-resolution time courses in closely monitored patients, combining cellular phenotyping (flow cytometry), single-cell transcriptome profiling (scRNA-seq), chromatin mapping...
Richter syndrome (RS) represents the development of high-grade lymphoma in patients with chronic lymphocytic leukaemia (CLL) or small (SLL) and presents a diagnostic therapeutic challenge an adverse prognosis. The genetic background morphology RS CLL treated chemoimmunotherapy is extensively characterised; however, our knowledge about targeted oral therapies should be extended. To understand morphologic molecular changes leading to Bruton's tyrosine kinase inhibitor, ibrutinib, BCL2...
Abstract This is the first large‐scale cross‐country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate incidence, types, and key prognostic factors secondary malignancies, assess impact on overall survival based retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL Czechia, Hungary, Poland; 10,312 (39.9%) were treated for in study periods between 2004 2016. Out patients, 1986 (19.3%) received FCR therapy line 779...
A dermatofibrosarcoma protuberans alacsony vagy közepes malignitású, ritka, rosszindulatú daganat. tumort a lassú, de agresszív lokális növekedés, az áttétképzési és magas helyi kiújulási arány jellemzi. Az elsődleges kezelés radikális sebészi eltávolítás hagyományos kimetszéssel Mohs-féle technikával. Pozitív szél, recidív tumor esetén radio-, kemoterápia, illetve újabban imatinib mesylat alkalmazható. Célkitűzés: szerzők 26, miatt onkológiai centrumban multidiszciplinárisan kezelt beteg...